Kim Dowook, Kim Yeseul, Sung Wonmo, Kim In Ah, Cho Jaeho, Lee Joo Ho, Grassberger Clemens, Byun Hwa Kyung, Chang Won Ick, Ren Leihao, Gong Ye, Wee Chan Woo, Hua Lingyang, Yoon Hong In
Department of Radiation Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, South Korea.
Department of Biomedical Engineering and of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Radiother Oncol. 2025 Feb;203:110695. doi: 10.1016/j.radonc.2024.110695. Epub 2024 Dec 19.
Atypical meningiomas are prevalent intracranial tumors with varied prognoses and recurrence rates. The role of adjuvant radiotherapy (ART) in atypical meningiomas remains debated. This study aimed to develop and validate a prognostic model incorporating machine learning techniques and clinical factors to predict progression-free survival (PFS) in patients with atypical meningiomas and assess the impact of ART.
A retrospective review of 669 patients from five institutions in Korea and China was conducted. Cox proportional hazards, gradient boosting machine, and random survival forest models were employed for comparative analysis, utilizing both internal and external validation sets. Model performance was assessed using Harrell's concordance index and permutation feature importance.
Of 581 eligible patients, age, post-operative platelet count, performance status, Simpson grade, and ART were identified as significant prognostic factors across all models. In the ART subgroup, age and tumor size were the top prognostic indicators. The Cox model outperformed other methods, achieving a training C-index of 0.73 (95 % CI: 0.72-0.73) and an external validation C-index of 0.74 (95 % CI: 0.73-0.74). The model effectively stratified patients into risk categories, revealing a differential impact of ART: low-risk patients in the active surveillance group showed a 5.6 % improvement in 5-year PFS with predicted ART addition, compared to a 15.9 % improvement in the high-risk group.
This multicenter study offers a validated prognostic model for atypical meningiomas, highlighting the need for tailored treatment plans. The model's ability to stratify patients into risk categories for PFS provides a valuable tool for clinical decision-making, potentially optimizing patient outcomes.
非典型脑膜瘤是常见的颅内肿瘤,预后和复发率各异。辅助放疗(ART)在非典型脑膜瘤中的作用仍存在争议。本研究旨在开发并验证一种结合机器学习技术和临床因素的预后模型,以预测非典型脑膜瘤患者的无进展生存期(PFS),并评估ART的影响。
对来自韩国和中国五个机构的669例患者进行回顾性研究。采用Cox比例风险模型、梯度提升机模型和随机生存森林模型进行比较分析,同时使用内部和外部验证集。使用Harrell一致性指数和排列特征重要性评估模型性能。
在581例符合条件的患者中,年龄、术后血小板计数、体能状态、辛普森分级和ART被确定为所有模型中的显著预后因素。在ART亚组中,年龄和肿瘤大小是首要的预后指标。Cox模型优于其他方法,训练C指数为0.73(95%CI:0.72 - 0.73),外部验证C指数为0.74(95%CI:0.73 - 0.74)。该模型有效地将患者分为不同风险类别,显示出ART的不同影响:主动监测组中的低风险患者在预测添加ART时5年PFS提高了5.6%,而高风险组提高了15.9%。
这项多中心研究为非典型脑膜瘤提供了一个经过验证的预后模型,强调了制定个性化治疗方案的必要性。该模型将患者分为PFS风险类别的能力为临床决策提供了有价值的工具,可能优化患者预后。